Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$11.91 +0.44 (+3.84%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$11.74
$12.31
50-Day Range
$7.15
$11.78
52-Week Range
$6.43
$29.74
Volume
12,872 shs
Average Volume
176,442 shs
Market Capitalization
$434.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.67
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Rapport Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 736th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rapport Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rapport Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Rapport Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    14.01% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently decreased by 12.86%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.01% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently decreased by 12.86%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Rapport Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for RAPP on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

Mise à disposition du rapport financier annuel 2024
Rapport Therapeutics (RAPP) and Its Rivals Critical Contrast
Trump Orders 'National Digital Asset Stockpile'
Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what could be the biggest wealth opportunity since Bitcoin's early days.
Rapport Therapeutics initiated with an Outperform at Citizens JMP
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $17.74 at the start of the year. Since then, RAPP shares have decreased by 32.9% and is now trading at $11.91.
View the best growth stocks for 2025 here
.

Rapport Therapeutics (NASDAQ:RAPP) posted its quarterly earnings data on Thursday, November, 7th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.07.

Rapport Therapeutics (RAPP) raised $136 million in an initial public offering on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share.

Rapport Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.10%), Alps Advisors Inc. (0.07%), Rhumbline Advisers (0.04%) and Catalyst Private Wealth LLC (0.03%).
View institutional ownership trends
.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Biopartners (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
11/07/2024
Today
5/02/2025
Next Earnings (Estimated)
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.67
High Stock Price Target
$35.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+184.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$418.63 million
Optionable
N/A
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners